Data from the phase 3 COMMANDS trial support the expanded European approval of frontline luspatercept for transfusion-dependent anemia in lower-risk myelodysplastic syndromes.
Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.
Treatment with rusfertide may reduce the use of phlebotomy and limit debilitating disease-related symptoms in patients with polycythemia vera based on findings from the phase 2 REVIVE trial.
Treatment with imetelstat produces robust activity in patients with relapsed/refractory myelodysplastic syndrome regardless of ring sideroblasts in the phase 3 IMerge trial.
Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.